Results 231 to 240 of about 50,773 (265)

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J., Cardona A.F., Anand V., Solà I.   +3 more
openaire   +2 more sources

Selective Janus kinase inhibitors come of age

Nature Reviews Rheumatology, 2019
Janus kinase (JAK) inhibitors (jakinibs) that target downstream signalling by a large range of cytokines are effective in treating autoimmune and rheumatic diseases. Newer jakinibs that selectively inhibit individual JAKs and a narrower spectrum of cytokines have now been developed, but how do these inhibitors compare with existing drugs?
John J, O'Shea, Massimo, Gadina
openaire   +2 more sources

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

Expert Opinion on Pharmacotherapy, 2014
Disordered signaling through the JAK/STAT pathway is a hallmark of myeloproliferative neoplasms (MPNs). Targeted therapies that inhibit and regulate this pathway are reasonable strategies for disease management. Only one JAK1/JAK2 inhibitor has gained FDA approval for treatment of myelofibrosis.
Allison, Rosenthal, Ruben A, Mesa
openaire   +2 more sources

Janus kinases inhibitors

Cahiers Santé Médecine Thérapeutique, 2022
El Mehdi Boudhar, M El Mandour, Abdelhafid Elguich, Hajar Sahimi, Hasna Hassikou   +4 more
openaire   +1 more source

Selective inhibitors of the Janus kinase Jak3—Are they effective?

Bioorganic & Medicinal Chemistry Letters, 2014
Jak3, together with Jak1, is involved in signal transduction initiated by cytokines signaling through the common gamma chain which are important in immune homeostasis and immune pathologies. Based on genetic evidence Jak3 has been considered to be an attractive target for immunosuppression.
Gebhard, Thoma, Peter, Drückes, Hans-Günter, Zerwes   +2 more
openaire   +2 more sources

Thromboembolism and Janus Kinase Inhibitors

Drug Safety, 2020
Fowzia Ibrahim, David L. Scott
openaire   +3 more sources

Advances in Janus Kinase Inhibitors for Vitiligo Treatment

Drug Research
Abstract Vitiligo is a cutaneous autoimmune disease characterized by the destruction of epidermal melanocytes leading to white patches with a global prevalence of about 0.5–2%, and patients’ quality of life are greatly affected by the change in appearance and social ...
Yue Liao, Wanlin Wang, Ruizhi Zhang, Jijun Huang, Jiamin Liu, Xiaokang Shan, Xiaojing Gao, Jin Bu, Yaping Tang, Erxia Shen   +9 more
openaire   +2 more sources

AN OVERVIEW OF JANUS KINASE INHIBITORS

Rheumatology Quarterly
With a better understanding of the pathogenesis of inflammatory rheumatic diseases, different treatments pathways have emerged. In recent years, Janus kinase inhibitors (JAKinibs) have become one of these treatment pathways. It has come into clinical use as an effective treatment agent, especially in rheumatoid arthritis and spondyloarthropathy. In the
openaire   +1 more source

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources

Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

Journal of the American Academy of Dermatology, 2023
, Mark Lee
exaly